Pharmacies and dispensing physicians should be on the alert for performance reports issued by certain PBMs with regard to prescription adherence or patient satisfaction surveys for providers participating in Medicare performance networks. ... Read More
As COVID-19 grips the national economy, pharmacies are not immune from the financial fallout. Challenging PBMs’ abusive DIR fee recoupments is more important than ever to preserve the viability of independent pharmacy. As pharmacies struggle to... Read More
Ohio legislators have introduced bipartisan Senate and House bills aimed at curbing excessive fees charged by insurers and Pharmacy Benefit Managers to pharmacies and providers participating in the 340B Drug Pricing Program. The 340B Program,... Read More
As another independent pharmacy closed its doors last week in Connecticut, the owner of the pharmacy identified that the rising costs of operations and direct and indirect remuneration (DIR) fees along with the decreasing reimbursement rates each... Read More
Pharmacies and physicians that dispense should be aware of Net Promoter Scores (“NPS”). A NPS is a survey metric used by PBMs purportedly to evaluate customer or patient satisfaction. The score is calculated from responses to the question, such... Read More
We first reported in late 2018 that Pharmacy Benefit Managers (PBMs) and Pharmacy Services Administrative Organizations (PSAOs) have implemented a new type of post-sale recoupment called Generic Effective Rate (GER) upon their member pharmacies. In... Read More
The 340B program is a federal discount drug program which requires pharmaceutical manufacturers to enter into an agreement, called a Pharmaceutical Pricing Agreement (PPA), with the Secretary of the Department of Health & Human Services in... Read More
Download the webinar slides. The specialty pharmacy industry has dramatically changed over the past few years and is now one of the fastest growing sources of revenue in the prescription drug marketplace. As a result, payers and PBMs... Read More
The impact of Direct and Indirect Remuneration ("DIR") fees on the specialty pharmacy industry cannot be overstated and has been widely reported in White Papers and industry news reports. However, the impact of DIR fees on the 340B sector is only... Read More
A White Paper by Frier Levitt examines the ongoing practice by Pharmacy Benefit Managers (PBMs) to increase corporate profits through murky "Direct and Indirect Remuneration" fees—commonly known as "DIR Fees"—charged to community oncology... Read More
